<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01843127</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-259-0165</org_study_id>
    <nct_id>NCT01843127</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.</brief_title>
  <official_title>A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes
      mellitus (T2DM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT)</measure>
    <time_frame>Days 5, 10, and 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose, serum insulin, and serum C-peptide AUCs during the SMT</measure>
    <time_frame>Days 5, 10, and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collapse under Acetaminophen PK</measure>
    <time_frame>Days 5 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma acetaminophen concentration-time curve from time 0 to 240 min (AUC0-240 min)</measure>
    <time_frame>Days 5 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collapse all under ranolazine pharmacokinetics (PK)</measure>
    <time_frame>Days 5 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma ranolazine concentrations (Ctrough)</measure>
    <time_frame>Days 5 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma ranolazine concentration during a dosing interval at steady state (Css,ave)</measure>
    <time_frame>Days 5 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma ranolazine concentration-time curve over dosing interval (AUCtau)</measure>
    <time_frame>Days 5 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent elimination half-life (t1/2) of ranolazine</measure>
    <time_frame>Days 5 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.</measure>
    <time_frame>From Screening to 7 days after the final dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo, Ranolazine, Exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranolazine, Placebo, Exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <arm_group_label>Placebo, Ranolazine, Exenatide</arm_group_label>
    <arm_group_label>Ranolazine, Placebo, Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo, Ranolazine, Exenatide</arm_group_label>
    <arm_group_label>Ranolazine, Placebo, Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <arm_group_label>Placebo, Ranolazine, Exenatide</arm_group_label>
    <arm_group_label>Ranolazine, Placebo, Exenatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 to 65 years old, inclusive

          -  Documented history of T2DM for ≥5 years

          -  Body mass index (BMI) 20.0 to 40.0 kg/m2, inclusive, at Screening

          -  Stable treatment (≥ 12 weeks) with metformin alone, a sulfonylurea alone, a
             meglitinide alone, or a combination of metformin with either a sulfonylurea or a
             meglitinide

          -  HbA1c ≥ 7.0% and ≤ 10.5%, inclusive, at Screening

          -  Fasting glucose within specific ranges, at Screening and after 14 +/-2 days of
             wash-out from prior oral anti-diabetic agents

          -  Fasting serum C-peptide ≥0.8 ng/mL, at Screening

          -  Estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2

          -  Ability and willingness to comply with all study procedures during the course of the
             study, including washout from oral anti-diabetic (OAD) agents approximately 2 weeks
             prior to Day -2 admission

          -  Females of childbearing potential must have a negative pregnancy test at Screening and
             on Day -2 admission and must agree to use highly effective contraception methods from
             Screening throughout study participation and for 14 days following the last dose of
             study drug.

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or secondary forms of diabetes

          -  History of acute diabetes complications

          -  Recent or significant heart conditions

          -  Uncontrolled hypertension

          -  QTc interval &gt; 500 msec by ECG at Screening or on Day -2 admission, a personal or
             family history of QTc prolongation, congenital long QT syndrome, or use of drugs that
             prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents,
             erythromycin, and certain antipsychotics (eg, ziprasidone)

          -  History of severe GI disease (e.g., gastroparesis)

          -  History of pancreatitis (acute or chronic)

          -  Current consumption of &gt; 14 alcoholic drinks per week, or more than 4 alcoholic drinks
             on any one day

          -  Current regular use of tobacco- or nicotine-containing products in excess of 10
             cigarettes per day or equivalent

          -  History of substance abuse within 12 months prior to Screening

          -  Significant hepatic disease, including, but not limited to, chronic active hepatitis
             and liver cirrhosis (Child-Pugh Class A, B, or C)

          -  History of malignancy within 5 years prior to Screening

          -  Significant thyroid disease

          -  Treatment with selected medications, as indicated in the protocol

          -  Prior treatment with open-label ranolazine or known hypersensitivity or intolerance to
             ranolazine or its excipients

          -  Known hypersensitivity or intolerance to GLP-1 mimetics

          -  Known hypersensitivity or intolerance to acetaminophen

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 2.5 X upper
             limit of normal (ULN)

          -  Total Bilirubin (TB) &gt; 2 mg/dL

          -  Hemoglobin &lt; 12 g/dL (for males) or &lt; 11 g/dL (for females)

          -  Positive for hepatitis B surface antigen

          -  Positive for anti-hepatitis C virus antibody

          -  Positive for human immunodeficiency virus-1 (HIV-1) antibody

          -  Positive urine drug screen

          -  Positive alcohol test

          -  Donation of blood or blood products to a blood bank, blood transfusion, or
             participation in a clinical study requiring withdrawal of &gt; 500 mL of blood during the
             6 weeks prior to Screening

          -  Females who are pregnant or breastfeeding

          -  Other condition(s) that, in the opinion of the investigator, would compromise the
             safety of the subject, would prevent compliance with the study protocol, or would
             compromise the quality of the clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SeaView Research, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Translational Research Institute-Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2013</study_first_posted>
  <last_update_submitted>March 28, 2014</last_update_submitted>
  <last_update_submitted_qc>March 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

